--- /home/app/data/titles/preprocessed/xml/21/2017/01/2017-01-03_9b868f32.xml	2021-11-04 17:22:29.195572941 -0400
+++ tmp/title_version_21_2017-01-03_9b868f32_preprocessed.xml	2021-11-04 17:30:24.527184967 -0400
@@ -96045,37 +96045,24 @@
 </P>
 <P>(c) <I>Record retention period.</I> You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.
 
+</DIV8>
+
+</DIV6>
 
+</DIV5>
 
-&gt;PART 216 - HUMAN DRUG COMPOUNDING 
-</P>
-<CONTENTS>
-<SUBPART>
-<RESERVED>Subpart A - General Provisions [Reserved]
-
-
-</RESERVED></SUBPART>
-<SUBPART>
-<HED>Subpart B - Compounded Drug Products
-</HED>
-<SECHD>Sec.
-</SECHD>
-<SECTNO>216.23</SECTNO>
-<SUBJECT>[Reserved]
-</SUBJECT>
-<SECTNO>216.24</SECTNO>
-<SUBJECT>Drug products withdrawn or removed from the market for reasons of safety or effectiveness.</SUBJECT></SUBPART></CONTENTS>
+
+<DIV5 N="216" TYPE="PART">
+<HEAD>PART 216 - HUMAN DRUG COMPOUNDING
+</HEAD>
 <AUTH>
 <HED>Authority:</HED><PSPACE>21 U.S.C. 351, 352, 353a, 353b, 355, and 371.
 </PSPACE></AUTH>
-</DIV8>
-
 <SOURCE>
 <HED>Source:</HED><PSPACE>64 FR 10944, Mar. 8, 1999, unless otherwise noted.
 
 
 </PSPACE></SOURCE>
-</DIV6>
 
 
 <DIV6 N="A" TYPE="SUBPART">
